[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 146″]
Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?
Want to know more about these podcast guests?
Vicken Karageozian, MD: https://ois.net/vicken-karageozian/